Paul Matteis
Stock Analyst at Stifel
(2.10)
# 2,973
Out of 4,996 analysts
111
Total ratings
41.89%
Success rate
-4.52%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEPG PepGen | Maintains: Buy | $9 → $12 | $5.07 | +136.69% | 3 | Sep 25, 2025 | |
| QURE uniQure | Maintains: Buy | $30 → $65 | $54.31 | +19.68% | 2 | Sep 24, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $494 → $455 | $385.74 | +17.96% | 19 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $166 → $174 | $142.00 | +22.54% | 9 | Jul 31, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $13.15 | +173.76% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $99.16 | -5.20% | 2 | May 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $446.40 | -22.72% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $1.74 | +14.94% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $28.96 | +10.50% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $14.44 | +121.61% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.80 | +89.66% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $3.10 | +29.03% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.95 | +153.16% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $17.82 | +236.70% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $27.89 | +29.08% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $53.85 | +61.56% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.59 | +31.63% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $64.09 | -17.30% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $21.05 | -0.24% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $11.92 | +143.29% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $137.37 | +108.92% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.77 | +195.42% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.53 | +239.94% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $3.86 | +1,195.34% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $12.40 | +158.06% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.42 | +1,801.41% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $15.34 | -8.74% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.80 | +841.18% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $90.50 | +275.71% | 1 | Dec 21, 2016 |
PepGen
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.07
Upside: +136.69%
uniQure
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $65
Current: $54.31
Upside: +19.68%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Hold
Price Target: $494 → $455
Current: $385.74
Upside: +17.96%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Buy
Price Target: $166 → $174
Current: $142.00
Upside: +22.54%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $13.15
Upside: +173.76%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $99.16
Upside: -5.20%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $446.40
Upside: -22.72%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $1.74
Upside: +14.94%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $28.96
Upside: +10.50%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.44
Upside: +121.61%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $5.80
Upside: +89.66%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $3.10
Upside: +29.03%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.95
Upside: +153.16%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $17.82
Upside: +236.70%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $27.89
Upside: +29.08%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $53.85
Upside: +61.56%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $26.59
Upside: +31.63%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $64.09
Upside: -17.30%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $21.05
Upside: -0.24%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $11.92
Upside: +143.29%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $137.37
Upside: +108.92%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.77
Upside: +195.42%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $3.53
Upside: +239.94%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $3.86
Upside: +1,195.34%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $12.40
Upside: +158.06%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.42
Upside: +1,801.41%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $15.34
Upside: -8.74%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.80
Upside: +841.18%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $90.50
Upside: +275.71%